Physician profile
Jonathan D Brown
NPI 1487009759
$2,209.89
in general payments reported to CMS, 2019-2025
23 companies · $385 in 2025
The $385 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $539 · 2022: $215 · 2023: $420 · 2024: $651 · 2025: $385.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,456.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,455.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kestra Medical Technology Services, INC. | $463.00 | 2023-2025 | Assure Wcd |
| Novartis Pharmaceuticals Corporation | $412.61 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $216.20 | 2021-2023 | Farxiga |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $163.19 | 2021-2024 | Lifevest |
| Amgen INC. | $149.03 | 2022-2024 | Repatha |
| Abbott Laboratories | $145.16 | 2021-2024 | Cardiomems |
| Janssen Pharmaceuticals, INC | $142.99 | 2021-2024 | Xarelto |
| Biotronik INC. | $66.82 | 2021 | |
| Irhythm Technologies, INC. | $60.20 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| Cvrx, INC. | $54.65 | 2025 | Barostim Neo System |
| Kiniksa Pharmaceuticals, LTD. | $46.05 | 2023 | Arcalyst |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.64 | 2024 | Jardiance |
| Scpharmaceuticals INC. | $43.60 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $39.15 | 2025 | Eliquis |
| Lexicon Pharmaceuticals, INC. | $25.16 | 2024 | Inpefa |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $24.95 | 2024 | Arcalyst |
| Heartflow, INC. | $24.04 | 2023 | Ffrct |
| Tactile Systems Technology INC | $18.24 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $15.57 | 2021 | |
| Boston Scientific Corporation | $13.92 | 2022 | |
| Amarin Pharma, INC. | $13.79 | 2021 | |
| Pfizer INC. | $13.50 | 2023 | |
| Merck Sharp & Dohme LLC | $13.43 | 2023 | Verquvo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.